GlassScriptPhysician profile
Nabeel A Hafeez
NPI 1205820982
$4,252.51
in general payments reported to CMS, 2019-2025
30 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $545 · 2021: $256 · 2022: $224 · 2023: $1,064 · 2024: $801 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $638.52 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $578.19 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $459.01 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $410.53 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $403.44 | 2019-2024 | Xarelto |
| Nuwellis, INC. | $290.84 | 2019-2020 | |
| Medtronic, INC. | $141.35 | 2023 | Micra |
| Janssen Scientific Affairs, LLC | $132.80 | 2024 | Xarelto |
| Shockwave Medical, INC | $128.60 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Heartflow, INC. | $128.01 | 2023-2025 | Ffrct |
| Boston Scientific Corporation | $123.53 | 2022-2023 | Watchman Flx |
| Inspire Medical Systems, INC. | $111.75 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $95.72 | 2021-2025 | Nexletol |
| Lantheus Medical Imaging, INC. | $85.57 | 2023-2024 | Definity |
| Edwards Lifesciences Corporation | $73.04 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.06 | 2019-2022 | |
| Cvrx, INC. | $51.70 | 2023 | Barostim Neo System |
| Astellas Pharma US INC | $42.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.41 | 2023 | Verquvo |
| Abbott Laboratories | $36.56 | 2024-2025 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $35.42 | 2023 | |
| Sanofi-Aventis U.S. LLC | $31.31 | 2019-2020 | |
| Ge Healthcare | $28.17 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $24.28 | 2023 | Arcalyst |
| Phadia US INC. | $19.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.56 | 2021 | |
| Impulse Dynamics (USA) INC. | $18.67 | 2023 | Optimizer |
| Philips North America LLC | $15.76 | 2023 | |
| Allergan, INC. | $14.98 | 2019 | |
| Baxter Healthcare | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.